Abstract
Chemotherapy induced peripheral neuropathy (CIPN) is a dose-limiting side effect of chemotherapy for which no prevention or cure exists. Cancer and cancer treatments can adversely affect nutritional status. Nutrition may play a role in development of CIPN, yet the relationship between nutrition and CIPN is not well understood. Common laboratory values measuring various aspects of nutrition (hemoglobin/hematocrit, vitamin B12, calcium, and magnesium) may be associated with CIPN. The aim of this systematic review is to evaluate the empirical evidence surrounding the relationship between laboratory measures of nutrition and CIPN among persons with cancer who received neurotoxic chemotherapy drugs. We conducted an extensive review of the literature to identify articles that evaluated relationships between laboratory measures of nutrition and CIPN. A total of eleven articles satisfied the inclusion/exclusion criteria. Participants in the studies had breast or colorectal cancer, lymphoma or multiple myeloma and were receiving a variety of neurotoxic drugs. Hemoglobin/hematocrit, vitamin D, albumin, and magnesium were associated with CIPN. The quality of the studies ranges from fair to good. Evidence suggests that low levels of the above-mentioned tests could be associated with CIPN but additional research is needed.
Highlights
Despite advances in the treatment of cancer, chemotherapy induced peripheral neuropathy (CIPN) remains a common, often dose-limiting adverse effect of multiple chemotherapeutic agents
Five studies examined laboratory measures associated with CIPN caused by oxaliplatin [13,14,15,16,19]
A prospective, observational study of 130 patients from Iran with stage III colorectal cancer treated with adjuvant capecitabine and oxaliplatin (CAPEOX) or infusional 5-FU and oxaliplatin (FOLFOX) sought to evaluate risk factors for chronic neuropathy [14]
Summary
Despite advances in the treatment of cancer, chemotherapy induced peripheral neuropathy (CIPN) remains a common, often dose-limiting adverse effect of multiple chemotherapeutic agents. CIPN is difficult to prevent or treat and adversely affects physical function and quality of life [4,5]. Dose modifications and treatment interruptions in response to the development of CIPN can adversely affect treatment efficacy and cancer outcomes [7]. Good nutrition is essential for the functioning of the peripheral nervous system. Deficiencies in vitamin B12, vitamin B1, folate, vitamin E, and copper independently contribute to the development of peripheral neuropathy, as do excess levels of vitamin B6 [8]. Cancer and cancer treatments can adversely affect nutritional status, including both intake and absorption of nutrients. Laboratory measures of nutrition provide better information about nutritional status than evaluation of dietary intake
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
